This is a Phase I, open-label, multi-center, competitive enrollment and dose-escalation study
of ALT-836 in combination with standard of care gemcitabine in participants who have locally
advanced or metastatic solid tumors. The purpose of this study is to determine the maximum
tolerated dose (MTD), and to assess the safety and pharmacokinetic profile of ALT-836 given
with gemcitabine. The clinical benefit, progression-free survival and overall survival of
study participants will also be assessed.